

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HANGZHOU TIGERMED CONSULTING CO., LTD.**

### **杭州泰格醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3347)**

## **ELECTION OF CHAIRMAN OF THE BOARD, APPOINTMENT OF MEMBERS OF EACH OF THE BOARD COMMITTEES, ENGAGEMENT OF SENIOR MANAGEMENT OF THE COMPANY, CHANGE IN THE LEGAL REPRESENTATIVE OF THE COMPANY AND ENGAGEMENT OF THE SECRETARY TO THE BOARD AND REPRESENTATIVE OF SECURITIES AFFAIRS**

Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) is pleased to announce that the sixth session of the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company comprises Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wen Zengyu as executive Directors, Mr. Wu Hao as an employee Director and Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu, Paul Yu Hay as independent non-executive Directors. At the first meeting of the sixth session of the Board convened by the Company on June 2, 2026, the Board considered and approved, inter alia, the election of the chairman of the Board, the appointment of members of each of the Board committees of the Company (collectively, the “**Board Committees**”), the engagement of senior management of the Company, the change in legal representative of the Company; and the engagement of the secretary to the Board and representative of securities affairs.

### **ELECTION OF CHAIRMAN OF THE BOARD**

In accordance with the relevant provisions of the articles of association of the Company (the “**Articles of Association**”), the Board has considered and approved the election of Dr. Ye Xiaoping as the chairman of the sixth session of the Board. His term of office shall commence on the date of consideration and approval by the Board (i.e. June 2, 2026) until the expiration date of the term of office of the sixth session of the Board.

Please refer to the circular of the Company dated April 30, 2026 for the biographical details and other information of Dr. Ye Xiaoping.

## **APPOINTMENT OF MEMBERS OF EACH OF THE BOARD COMMITTEES**

The Board has considered and approved the members of the sixth session of the Board Committees to be as follows:

- (1) the audit committee of the Board will comprise Mr. Siu, Paul Yu Hay, Mr. Yuan Huagang and Ms. Liu Yuwen, and will be chaired by Mr. Siu, Paul Yu Hay;
- (2) the remuneration and evaluation committee of the Board will comprise Mr. Yuan Huagang, Mr. Siu, Paul Yu Hay, Ms. Cao Xiaochun and will be chaired by Mr. Yuan Huagang;
- (3) the strategic committee of the Board will comprise Dr. Ye Xiaoping, Mr. Wu Hao and Mr. Yuan Huagang, and will be chaired by Dr. Ye Xiaoping; and
- (4) the nomination committee of the Board will comprise Ms. Liu Yuwen, Mr. Wen Zengyu, Mr. Siu, Paul Yu Hay and will be chaired by Ms. Liu Yuwen.

The term of office of the members of the Board committees shall commence on the date of consideration and approval by the Board (i.e. June 2, 2026) until the expiration date of the term of office of the sixth session of the Board.

## **ENGAGEMENT OF SENIOR MANAGEMENT OF THE COMPANY**

The Board has considered and approved the appointment of Mr. Wen Zengyu as the general manager of the Company, Mr. Wu Hao as the co-president of the Company, Mr. Peng Yifei as the chief operating officer of the Company and Ms. Yang Chengcheng as the chief financial officer of the Company. The terms of their appointments shall commence on the date of consideration and approval by the Board (i.e. June 2, 2026) until the expiration date of the term of office of the sixth session of the Board.

## **CHANGE IN THE LEGAL REPRESENTATIVE OF THE COMPANY**

According to article 8 of the Articles of Association: “The Company’s legal representative is the general manager of the Company. Where the general manager resigns, he shall be deemed to have resigned from the position of legal representative simultaneously. Where the legal representative resigns, the Company shall determine a new legal representative within thirty days from the date of the resignation of the legal representative. Before the change of the Company’s legal representative is completed, the original legal representative shall continue to perform his or her duties.”

As the Board has appointed Mr. Wen Zengyu as the general Manager of the Company, accordingly, pursuant to Article 8 of the Articles of Association, the Board has considered and approved the change of the legal representative of the Company from Ms. Cao Xiaochun to Mr. Wen Zengyu.

#### **ENGAGEMENT OF THE SECRETARY TO THE BOARD AND REPRESENTATIVE OF SECURITIES AFFAIRS**

The Board has considered and approved Ms. Li Xiaori as the secretary to the Board and Ms. Ruan Xinhui as the representative of securities affairs of the Company. The terms of their appointments shall commence on the date of consideration and approval by the Board (i.e. June 2, 2026) until the expiration date of the term of office of the sixth session of the Board.

By order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
*Chairman*

Hong Kong, June 2, 2026

*As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee Director is Mr. Wu Hao; the independent non-executive Directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu, Paul Yu Hay.*